This drug is available at a middle level co-pay. vecuronium decreases levels of haloperidol by pharmacodynamic antagonism. unspecified interaction mechanism. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. haloperidol will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Effect of interaction is not clear, use caution. desflurane and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. levorphanol and haloperidol both increase sedation. midazolam intranasal, haloperidol. nelfinavir will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Applies only to oral form of both agents. procarbazine, haloperidol. Serious - Use Alternative (1)eribulin and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Either increases effects of the other by pharmacodynamic synergism. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor Closely (1)haloperidol will increase the level or effect of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Panobinostat is known to significantly prolong QT interval. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. haloperidol will increase the level or effect of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Lonafarnib is a sensitive CYP3A4 substrate. lefamulin will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid. Either increases toxicity of the other by QTc interval. Additive anticholinergic effects, possible hypoglycemia. Monitor Closely (2)haloperidol and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Monitor Closely (1)haloperidol increases and phenylephrine decreases sedation. haloperidol, secobarbital. Serious - Use Alternative (1)haloperidol will increase the level or effect of olaparib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved. Use Caution/Monitor.haloperidol and clozapine both increase QTc interval. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)haloperidol will increase the level or effect of irinotecan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. It is also used to control the symptoms of Tourette's disorder. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. Avoid or Use Alternate Drug.ceritinib will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Last updated on May 31, 2023. maprotiline and haloperidol both increase QTc interval. haloperidol will increase the level or effect of irinotecan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. butabarbital and haloperidol both increase sedation. Minor (1)haloperidol will increase the level or effect of loratadine by affecting hepatic enzyme CYP2D6 metabolism. Monitor Closely (1)haloperidol and isradipine both increase QTc interval. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Monitor Closely (3)propantheline decreases levels of haloperidol by inhibition of GI absorption. quetiapine, haloperidol. Modify Therapy/Monitor Closely. haloperidol increases and salmeterol decreases sedation. Avoid or Use Alternate Drug. Use Caution/Monitor.pancuronium decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. Avoid or Use Alternate Drug. haloperidol and pitolisant both increase QTc interval. oxybutynin transdermal decreases effects of haloperidol by pharmacodynamic antagonism. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IM decreases levels of haloperidol by inhibition of GI absorption. Use Caution/Monitor. If coadministration with moderate CYP3A inhibitors cannot be avoided, reduce olaparib dose to 200 mg (capsule) or 150 mg (tablet) PO BID. Use Caution/Monitor.efavirenz and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)haloperidol will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Decreased conversion of oxycodone to active metabolite morphine. Effect of interaction is not clear, use caution. Monitor Closely (1)linezolid, haloperidol. Use Caution/Monitor. Use Caution/Monitor. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Use Caution/Monitor. Coadministration with drugs that lower seizure threshold may increase this risk. haloperidol will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Limit dosages and durations to the minimum required. ketamine and haloperidol both increase sedation. Monitor Closely (1)triazolam and haloperidol both increase sedation. Monitor Closely (1)gilteritinib and haloperidol both increase QTc interval. haloperidol and trimethoprim both increase QTc interval. unspecified interaction mechanism. Either increases effects of the other by pharmacodynamic synergism. haloperidol and dosulepin both increase sedation. Use Caution/Monitor. haloperidol and olodaterol inhaled both increase QTc interval. (Theoretical interaction). Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. henbane decreases levels of haloperidol by inhibition of GI absorption. haloperidol increases and lisdexamfetamine decreases sedation. Minor/Significance Unknown. Avoid or Use Alternate Drug. quinupristin/dalfopristin increases levels of haloperidol by decreasing metabolism. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. clobazam will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. If concurrent use cannot be avoided, cautious dosing and telemetric monitoring is advised. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. phenobarbital and haloperidol both increase sedation. Monitor Closely (1)bosentan will decrease the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. haloperidol and clomipramine both increase sedation. Use Caution/Monitor. Monitor Closely (1)pentobarbital and haloperidol both increase sedation. Use Caution/Monitor.aripiprazole and haloperidol both increase QTc interval. Use Caution/Monitor. Use Caution/Monitor. Reduce zanubrutinib (a CYP3A4 substrate) to 80 mg PO BID to when coadministered with a moderate CYP3A4 inhibitor. Use Caution/Monitor. paroxetine will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. If you are using the liquid form of the medication, use the measuring dropper provided in the package to measure your dose. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. haloperidol increases and phendimetrazine decreases sedation. erythromycin lactobionate and haloperidol both increase QTc interval. Effect of interaction is not clear, use caution. Use Caution/Monitor. Tell patients to immediately report any signs/symptoms of neutropenia/leukopenia, neuroleptic malignant syndrome, or tardive dyskinesia. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties. Use Caution/Monitor. fesoterodine decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. Children younger than 3 years of ageUse and dose must be determined by the doctor. Avoid or Use Alternate Drug. Adjust dose of drugs that are CYP3A4 substrates as necessary.fedratinib will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Serious - Use Alternative (2)fentanyl transdermal, haloperidol. Avoid or Use Alternate Drug. Limit dosages and durations to the minimum required. Monitor Closely (1)rizatriptan, haloperidol. Applies only to oral form of both agents. If coadministation of naloxegol with moderate CYP3A4 inhibitors is unavoidable, reduce naloxegol dose to 12.5 mg qDay. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Monitor Closely (1)loprazolam and haloperidol both increase sedation. Use Caution/Monitor. Modify Therapy/Monitor Closely. Use Caution/Monitor. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. Use Caution/Monitor. This product is available in the following dosage forms: Oil Solution Before Using Use Caution/Monitor. trifluoperazine and haloperidol both increase QTc interval. PDF HALDOL Decanoate 50 (haloperidol) HALDOL Decanoate 100 (haloperidol Initial oral doses should be given within 12 to 24 hours after the last parenteral dose. Use Caution/Monitor.belladonna and opium decreases levels of haloperidol by inhibition of GI absorption. Use Caution/Monitor. Monitor Closely (1)encorafenib, haloperidol. Monitor for hypotension, respiratory depression, and profound sedation.haloperidol will increase the level or effect of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. haloperidol and ramelteon both increase sedation. Additive anticholinergic effects, possible hypoglycemia. Avoid or Use Alternate Drug. Minor/Significance Unknown. Monitor Closely (2)asenapine transdermal and haloperidol both increase QTc interval. haloperidol and motherwort both increase sedation. frovatriptan, haloperidol. haloperidol and mefloquine both increase QTc interval. Monitor Closely (1)haloperidol will increase the level or effect of palbociclib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)almotriptan, haloperidol. unspecified interaction mechanism. Modify Therapy/Monitor Closely. Use Caution/Monitor. haloperidol and olanzapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Monitor Closely (1)haloperidol increases and midodrine decreases sedation. Use Caution/Monitor. Profound sedation, respiratory depression, coma, and death may result if coadministered. Monitor Closely (1)dasatinib and haloperidol both increase QTc interval. Modify Therapy/Monitor Closely. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor.haloperidol increases effects of methscopolamine by pharmacodynamic synergism. haloperidol and moxifloxacin both increase QTc interval. haloperidol will increase the level or effect of venetoclax by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. rapacuronium decreases levels of haloperidol by inhibition of GI absorption. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. unspecified interaction mechanism. Effect of interaction is not clear, use caution. Use Caution/Monitor. haloperidol and octreotide both increase QTc interval. Monitor Closely (1)haloperidol increases and norepinephrine decreases sedation. Modify Therapy/Monitor Closely. Use Caution/Monitor. Avoid or Use Alternate Drug. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Serious - Use Alternative (1)idelalisib will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (2)haloperidol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction). Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Avoid or Use Alternate Drug. istradefylline will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. haloperidol and solifenacin both increase QTc interval. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction). Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. Monitor Closely (1)haloperidol and melatonin both increase sedation. Contraindicated. Resume previous entrectinib dose after discontinuing moderate CYP3A inhibitor for 3-5 elimination half-lives. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (2)buprenorphine subdermal implant and haloperidol both increase sedation. Monitor Closely (1)haloperidol increases and yohimbine decreases sedation. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. haloperidol will increase the level or effect of fesoterodine by affecting hepatic enzyme CYP2D6 metabolism. Avoid coadministration of moderate CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction). Monitor for signs of opioid withdrawal. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)teduglutide increases levels of haloperidol by Other (see comment). Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity. Serious - Use Alternative (1)haloperidol decreases effects of pramipexole by pharmacodynamic antagonism. Effect of interaction is not clear, use caution. haloperidol increases and dopexamine decreases sedation. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias. Use Caution/Monitor. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate. Monitor Closely (2)haloperidol will increase the level or effect of daridorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Potential for additive anticholinergic effects. Monitor for hypotension, respiratory depression, and profound sedation. Haldol Dosage Generic name: Haloperidol lactate 5mg in 1mL Dosage form: injection Drug class: Miscellaneous antipsychotic agents Medically reviewed by Drugs.com. Use Caution/Monitor. unspecified interaction mechanism. lithium, haloperidol. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. haloperidol increases effects of atracurium by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. Use Caution/Monitor. haloperidol and loxapine inhaled both increase sedation. haloperidol will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. haloperidol and levofloxacin both increase QTc interval. Coadministration with moderate CYP3A4 inhibitors, reduce ibrutinib dose to 280 mg qDay (B-cell malignancies) or 420 mg qDay (graft versus host disease). carbamazepine will decrease the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. haloperidol and isradipine both increase QTc interval. Additive anticholinergic effects, possible hypoglycemia. Risk of hyperthermia if haloperidol admin. Monitor patients already on buprenorphine subdermal implant who require newly-initiated treatment with CYP3A4 inhibitors for signs and symptoms of overmedication. haloperidol will increase the level or effect of naloxegol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)adagrasib, haloperidol. haloperidol increases effects of ipratropium by pharmacodynamic synergism. tetrabenazine and haloperidol both increase QTc interval. Modify Therapy/Monitor Closely. Either increases toxicity of the other by pharmacodynamic synergism. What are the side effects of haloperidol? Minor/Significance Unknown.haloperidol will increase the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Monitor Closely (1)rifapentine will decrease the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Minor/Significance Unknown. unspecified interaction mechanism. fentanyl, haloperidol. Oral solution: Administer with a calibrated dropper. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. buprenorphine buccal and haloperidol both increase QTc interval. Monitor Closely (1)lormetazepam and haloperidol both increase sedation. Monitor Closely (1)rolapitant will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. Use Caution/Monitor. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. After discontinuing the CYP3A4 inhibitor for 3 elimination half-lives, may resume previous pemigatinib dose. haloperidol increases effects of trospium chloride by pharmacodynamic synergism. Data sources include IBM Watson Micromedex (updated 3 July 2023), Cerner Multum (updated 10 July 2023), ASHP (updated 10 July 2023) and others. Use Caution/Monitor. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Use Caution/Monitor. Effect of interaction is not clear, use caution. Comment: Haloperidol may induce hyperammonemia; monitor ammonia levels closely when coadministered with glycerol phenylbutyrate. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Use Caution/Monitor.haloperidol and sertraline both increase QTc interval. Use Caution/Monitor.atropine IV/IM decreases levels of haloperidol by pharmacodynamic antagonism. Monitor Closely (1)diphenoxylate hcl and haloperidol both increase sedation. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).This medication may make you sweat less, making you more likely to get heat stroke. Use Caution/Monitor. haloperidol and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. ketoconazole will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (2)ranolazine will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. SIDE EFFECTS: Dizziness, lightheadedness, drowsiness, difficulty urinating, sleep disturbances, headache, or anxiety may occur. Serious - Use Alternative (1)selinexor, haloperidol. If not feasible, avoid use of abametapir. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. ECG monitoring is recommended if coadministered. Additive anticholinergic effects, possible hypoglycemia. Applies only to oral form of both agents. Either increases toxicity of the other by pharmacodynamic synergism. Additive anticholinergic effects, possible hypoglycemia. Monitor Closely (3)hyoscyamine decreases levels of haloperidol by inhibition of GI absorption. Avoid or Use Alternate Drug. Use Caution/Monitor. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction). Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence. The frequency of IM administration should be determined by patient response and may be given as often as every hour. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. Use Caution/Monitor. Modify Therapy/Monitor Closely. This document does not contain all possible drug interactions. Use Caution/Monitor. Use Caution/Monitor.haloperidol increases effects of cyclobenzaprine by pharmacodynamic synergism. crizotinib and haloperidol both increase QTc interval. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. haloperidol will increase the level or effect of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Your list will be saved and can be edited at any time. Avoid coadministration of avapritinib with moderate CYP3A4 inhibitors. Monitor for increased risk of QTc interval prolongation.Serious - Use Alternative (2)ivosidenib and haloperidol both increase QTc interval. Monitor Closely (1)haloperidol will increase the level or effect of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rapacuronium decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. Use Caution/Monitor. abametapir will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Limit dosages and durations to the minimum required. haloperidol will increase the level or effect of fentanyl transmucosal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Use Caution/Monitor. during barbiturate withdrawal. Effect of interaction is not clear, use caution. haloperidol will increase the level or effect of benzhydrocodone/acetaminophen by affecting hepatic enzyme CYP2D6 metabolism. Mechanism: pharmacodynamic synergism. unspecified interaction mechanism. Prevents conversion of codeine to its active metabolite morphine. haloperidol increases and epinephrine decreases sedation. haloperidol and paroxetine both increase QTc interval. Monitor Closely (1)dimenhydrinate and haloperidol both increase sedation. Use Caution/Monitor. Minor (1)haloperidol will increase the level or effect of perhexiline by affecting hepatic enzyme CYP2D6 metabolism.
Zephyr Road Williston, Vt, Is Macy's And Bloomingdale's The Same Company, Lake Venice Golf Club, Why Do Guys Get Mad When You Cry, Articles H